Mount Tam Biotechnologies Inc (OTCMKTS:MNTM) over the last month is up over 30%. YTD that number rises over 100% and the catalyst for MNTM has to do with a European patent approval for its mTOR inhibitor, TAM-01. TAM-01 has been shown to be efficacious in pre-clinical animal models of SLE while significantly reducing or abolishing the undesirable side effects of other known mTOR inhibitors such as rapamycin.
According to the release, the patent claims TAM-01 composition of matter, uses for the treatment of lupus or multiple sclerosis, and processes for preparing TAM-01. The patent, published as EP2797929, is owned by The Buck Institute for Research on Aging and licensed exclusively to Mount Tam, further strengthening Mount Tam’s strong intellectual property position relating to TAM-01 in the United States and Japan. “This is another important step forward for Mount Tam, one that significantly expands both our market opportunities globally and our strategic partnering opportunities” said Mount Tam CEO Richard Marshak.
Mount Tam Biotechnologies Inc (OTCMKTS:MNTM) formerly TabacaleraYsidron, Inc., is a specialty biopharmaceutical company established to develop and bring to market a portfolio of pharmaceutical products targeting the treatment of autoimmune diseases.
MNTM was established to develop, optimize and bring to market novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. Mount Tam is focused on the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. Mount Tam believes it has an industry leadership position in developing therapeutic products which address aberrations in the mTOR pathway, and is confident that both TAM-01 and TAM-03 are significantly differentiated from currently marketed rapalogs and have the potential to bring significant benefits to patients.
Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The licensed assets are highly target-specific polyketides. Mount Tam is advancing its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has largely completed non-GLP pre-clinical development. The lead indication for TAM-01 is expected to be the treatment of SLE. Mount Tam is also advancing follow-on compounds through the discovery process and is looking at a broad range of disease areas where novel mTOR inhibitors have been shown to have the potential to address unmet need.
Find out when $MNTM reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
While the patent in Europe is a nice boost in confidence for MNTM’s novel technology, current investors I am sure want to see some sales and some progress before they start jumping for joy. MNTM has no significant operating history and had a cumulative net loss from inception (August 13, 2014) to September 30, 2017 of $6,539,690. The Company has a working capital deficit of $1,231,497 as of September 30, 2017. So, it goes without saying that MNTM has been funded through debt and equity financings.
Mount Tam Biotechnologies Inc (OTCMKTS:MNTM) has a market cap of $7.4M and a float of 35.72M. MNTM was plagued with selling pressure earlier in the month but has fought back. We are interested to see what is next for this biotech and if it can string together a solid rally. Sign-up for continuing coverage on shares of $MNTM stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $MNTM, either long or short, and we have not been compensated for this article.